Similar articles

• Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.

  Hess CN, Clare RM, Neely ML, Tricoci P, Mahaffey KW, James SK, Alexander JH, Held C, Lopes RD, Fox KAA, White HD, Wallentin L, Armstrong PW, Harrington RA, Ohman EM, Roe MT. Hess CN, et al. Am Heart J. 2017 May;187:194-203. doi: 10.1016/j.ahj.2017.01.016. Epub 2017 Feb 21. Am Heart J. 2017. PMID: 28454804
• Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.

  Gibson CM, Mega JL, Burton P, Goto S, Verheugt F, Bode C, Plotnikov A, Sun X, Cook-Bruns N, Braunwald E. Gibson CM, et al. Am Heart J. 2011 May;161(5):815-821.e6. doi: 10.1016/j.ahj.2011.01.026. Am Heart J. 2011. PMID: 21570509 Clinical Trial.
• Predictors and Impact of In-Hospital Recurrent Myocardial Infarction in Patients With Acute Coronary Syndrome: Findings From Gulf RACE-2.

  Al Saleh AS, Alhabib KF, Alsheik-Ali AA, Sulaiman K, Alfaleh H, Alsaif S, Al Mahmeed W, Asaad N, Amin H, Al-Motarreb A, Al Suwaidi J, Hersi AS. Al Saleh AS, et al. Angiology. 2017 Jul;68(6):508-512. doi: 10.1177/0003319716674855. Epub 2016 Oct 26. Angiology. 2017. PMID: 27784731
• Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials.

  Swahn E, Alfredsson J, Afzal R, Budaj A, Chrolavicius S, Fox K, Jolly S, Mehta SR, de Winter R, Yusuf S. Swahn E, et al. Eur Heart J. 2012 Jan;33(1):51-60. doi: 10.1093/eurheartj/ehp009. Epub 2009 Feb 7. Eur Heart J. 2012. PMID: 19202154 Review.
• Updates in antiplatelet agents used in cardiovascular diseases.

  Cheng JW. Cheng JW. J Cardiovasc Pharmacol Ther. 2013 Nov;18(6):514-24. doi: 10.1177/1074248413499971. J Cardiovasc Pharmacol Ther. 2013. PMID: 24213473 Review.